JP2002532434A5 - - Google Patents

Download PDF

Info

Publication number
JP2002532434A5
JP2002532434A5 JP2000587797A JP2000587797A JP2002532434A5 JP 2002532434 A5 JP2002532434 A5 JP 2002532434A5 JP 2000587797 A JP2000587797 A JP 2000587797A JP 2000587797 A JP2000587797 A JP 2000587797A JP 2002532434 A5 JP2002532434 A5 JP 2002532434A5
Authority
JP
Japan
Prior art keywords
vlp
pharmaceutical composition
therapeutic vaccine
vaccine according
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000587797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002532434A (ja
JP5274737B2 (ja
Filing date
Publication date
Priority claimed from AUPP7653A external-priority patent/AUPP765398A0/en
Application filed filed Critical
Publication of JP2002532434A publication Critical patent/JP2002532434A/ja
Publication of JP2002532434A5 publication Critical patent/JP2002532434A5/ja
Application granted granted Critical
Publication of JP5274737B2 publication Critical patent/JP5274737B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000587797A 1998-12-11 1999-12-13 パピローマウイルス感染の治療方法 Expired - Lifetime JP5274737B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPP7653 1998-12-11
AUPP7653A AUPP765398A0 (en) 1998-12-11 1998-12-11 Treatment of papillomavirus infections
PCT/AU1999/001108 WO2000035478A1 (en) 1998-12-11 1999-12-13 Treatment of papillomavirus infections
AU7653 2000-05-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010261979A Division JP2011037902A (ja) 1998-12-11 2010-11-25 パピローマウイルス感染の治療方法

Publications (3)

Publication Number Publication Date
JP2002532434A JP2002532434A (ja) 2002-10-02
JP2002532434A5 true JP2002532434A5 (cg-RX-API-DMAC7.html) 2007-04-19
JP5274737B2 JP5274737B2 (ja) 2013-08-28

Family

ID=3811858

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000587797A Expired - Lifetime JP5274737B2 (ja) 1998-12-11 1999-12-13 パピローマウイルス感染の治療方法
JP2010261979A Pending JP2011037902A (ja) 1998-12-11 2010-11-25 パピローマウイルス感染の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010261979A Pending JP2011037902A (ja) 1998-12-11 2010-11-25 パピローマウイルス感染の治療方法

Country Status (12)

Country Link
US (2) US6867033B1 (cg-RX-API-DMAC7.html)
EP (1) EP1144005B1 (cg-RX-API-DMAC7.html)
JP (2) JP5274737B2 (cg-RX-API-DMAC7.html)
KR (1) KR100617485B1 (cg-RX-API-DMAC7.html)
AT (1) ATE344053T1 (cg-RX-API-DMAC7.html)
AU (1) AUPP765398A0 (cg-RX-API-DMAC7.html)
CA (1) CA2353866C (cg-RX-API-DMAC7.html)
DE (1) DE69933891T2 (cg-RX-API-DMAC7.html)
DK (1) DK1144005T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ512850A (cg-RX-API-DMAC7.html)
WO (1) WO2000035478A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA997638B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2284287T3 (es) * 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
FR2802426B1 (fr) * 1999-12-15 2004-04-02 Neovacs Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
EP1422526A1 (en) * 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
US10513541B2 (en) 2015-12-04 2019-12-24 Xiamen University Mutant of L1 protein of human papillomavirus type 11
WO2019081750A1 (en) * 2017-10-27 2019-05-02 Statens Serum Institut VACCINE AGAINST POLYGENIC INFLUENZA
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1359156B1 (en) 1991-07-19 2007-03-07 University of Queensland Vaccine against Human Papillomavirus (Type 18)
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
ES2264126T3 (es) * 1994-05-16 2006-12-16 MERCK & CO., INC. Vacunas contra el papilomavirus.
DE69531256T2 (de) * 1994-09-06 2004-05-27 Scan-Web I/S Verfahren und system zur herstellung von breiten, luftgelegten papierbahnen enthaltend ein absorbierendes pulver
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
AU4258297A (en) 1996-09-11 1998-04-02 Merck & Co., Inc. Papillomavirus vaccine formulation
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ES2273376T3 (es) 1996-12-20 2007-05-01 MERCK & CO., INC. Formulaciones de vacunas recombinantes frente a papilomas.
WO1998044944A2 (en) * 1997-04-08 1998-10-15 Merck & Co., Inc. Stabilized human papillomavirus formulations
DE19735118C1 (de) 1997-08-13 1998-08-13 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties

Similar Documents

Publication Publication Date Title
Bell et al. A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model
EP1410805B1 (en) Vaccine against HPV
Stanley Progress in prophylactic and therapeutic vaccines for human papillomavirus infection
Mossadegh et al. Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells
HK1244695A1 (zh) Hpv颗粒及其用途
Tjalma et al. Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer
JPH11504801A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
Huber et al. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types
EP0692028B1 (en) Pharmaceuticals based on papillomaviruses
JP2007507207A5 (cg-RX-API-DMAC7.html)
JP2010263899A (ja) L2ペプチドを含むキメラ・ヒト・パピローマウイルス16l1タンパク質、それから調製したウイルス様粒子および該粒子の調製方法
Roden et al. Opportunities to improve the prevention and treatment of cervical cancer
Bian et al. Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice
JP5274737B2 (ja) パピローマウイルス感染の治療方法
CZ20021023A3 (cs) Vakcína
AU755242B2 (en) Medicament for preventing or treating papilloma virus-specific tumors
Frazer HPV vaccines and the prevention of cervical cancer
Onon et al. The use of vaccines in treating cervical cancer: present status and future prospects
Green et al. Development of a topical protein therapeutic for human papillomavirus and associated cancers
Dillner Prospects for vaccination
US6926897B1 (en) Medicament for the avoidance or treatment of papillomavirus-specific tumour
AU3598999A (en) Formulation having a papilloma virus-specific protein, and the production and use thereof
WO2010056148A1 (ru) Мукозальная вакцина для иммунотерапии заболеваний, обусловленных вирусами папилломы человека
Im et al. Prevention of cervical cancer with vaccines
Deng et al. The preparation of human papillomavirus type 58 vaccine and exploring its biological activity and immunogenicity in vitro